Anemia, hypoxia and transfusion in patients with cervix cancer: a review

Fyles, Anthony; Milosevic, Michael; Pintilie, Melania; Syed, A.M. Nisar; Hill, Richard P.

doi:10.1016/s0167-8140(00)00245-0

Cited by 129 publications

(93 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fyles et al found that hemoglobin levels prior to and during treatment were strongly correlated with tumor size (Fyles et al, 2000). Marchal et al suggested that anemia was correlated with patient survival, and it appeared to be one of the most powerful prognostic factors after clinical stage and tumor size, but it has not been proven to be an independent factor (Marchal et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Clinical and Pathological Factors Related to the Prognosis of Chinese Patients with Stage Ⅰb To Ⅱb Cervical Cancer

Xie

Song²,

Cui³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical and Pathological Factors Related to the Prognosis of Chinese Patients with Stage Ⅰb To Ⅱb Cervical Cancer

Xie

Song²,

Cui³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…We added irinotecan to 5-fluorouracil in our study for two reasons: Owing to its high activity in advanced colorectal cancer (Douillard et al, 2000;Saltz et al, 2000) irinotecan appears particularly suited for intensified induction therapy; in addition, several studies have documented the radiosensitising properties of irinotecan (Boothmann et al, 1987;Boscia et al, 1993;Omura et al, 1997;Chen et al, 1999) that were observed even under hypoxic conditions (Boscia et al, 1993). As hypoxia may have an adverse effect on the radiosensitivity of cells (Kumar, 2000;Fyles et al, 2000), irinotecan may be particularly useful as a constituent of chemoradiotherapy programmes in patients with bulky pelvic tumours and poor blood supply that often contain hypoxic regions.…”

Section: Discussionmentioning

confidence: 99%

Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer

Klautke¹,

Feyerherd

Ludwig

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

This study aimed to evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy intensified with irinotecan in patients with locally advanced rectal cancer. Eligible patients had nonmetastatic disease at a locally advanced stage that made R0 resection and sphincter preservation uncertain. They received preoperative radiation over 6 weeks to 45 Gy and boost of 5.4 Gy and concurrent continuous infusion 5-fluorouracil 250 mg m À2 day À1 and weekly irinotecan 40 mg m À2 . In all, 37 patients entered the study. T stage at baseline as determined by ultrasound was T2/T3/T4 in 2/19/16 patients; 31 patients had lymph node involvement. The predominant toxicity was diarrhoea (grade 3/4 in 10/2 patients). Haematologic toxicity and surgical complications were moderate. Among 36 patients undergoing surgery, 32 (89%) had R0 resection and 23 (64%) sphincter preservation. Pathologic complete response (pCR) was achieved in eight (22%) of 36 patients, and 10 patients (28%) had only microscopic residual disease. At 4 years, overall survival was 66%, disease-free survival 73%, local relapse rate 7%, and distant failure rate 24%. Extent of resection and postoperative nodal status were significant predictors of overall and disease-free survival. Intensified neoadjuvant chemoradiotherapy with irinotecan can be safely administered and results in a high pCR rate.

show abstract

“…A considerable number of studies report radiotherapy and chemotherapy to be more effective under well-oxygenated conditions. Anemia might contribute to reduce tumor oxygenation via reduced oxygen delivery to the tumor [26]. In vitro and animal models have shown that cellular hypoxia, the consequence of anemia, may provide a selection pressure for tumor cells with higher rate of mutation, which may ultimately result in increased metastatic potential, increased cellular growth, therapy resistance, and decreased apoptotic potential [27].…”

Section: Discussionmentioning

confidence: 99%

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

Ferrero¹,

Zola²,

Mazzola³

et al. 2004

Gynecologic Oncology

View full text Add to dashboard Cite

Objective. The primary aim of this study was to evaluate the prognostic and predictive value of pretreatment serum hemoglobin level (Hb) in advanced ovarian cancer; second aim was to perform a preliminary investigation of intratumoral microvessel density (IMD).Methods. The influence on survival and response to treatment of several clinico-pathological features, including Hb, was analyzed in 72 patients with advanced ovarian cancer. IMD was assessed in tumor specimens of 25 of the 72 patients to compare three different endothelial markers: anti-FactorVIII, anti-CD31 and anti-CD34. In this subgroup of patients, a preliminary analysis of the prognostic and predictive value of IMD, and its relationship with Hb and other clinico-pathological features, was performed.Results. Hb z 12 g/dl was significantly associated with a better overall survival in univariate analysis ( P = 0.0181) and was the only independent prognostic variable in multivariate analysis ( P = 0.0160). Hb was directly related to progression-free survival ( P = 0.0240) and complete response to treatment ( P = 0.016). In the preliminary investigation of IMD, mean microvessel count did not show any significant difference among the three endothelial markers used, but anti-CD34 revealed a more consistent staining reaction. The relationship between IMD and complete response to treatment was found near to statistical significance ( P = 0.05); Hb and IMD were inversely related (r = À0.47; P = 0.045).Conclusions. Hb has a prognostic and predictive value in advanced ovarian cancer. In our preliminary study, which was performed on a limited number of patients, we found anti-CD34 to be an optimal marker for IMD determination, IMD to be a possible predictive factor of complete response to treatment, and IMD and Hb to be inversely related. D

show abstract

Anemia, hypoxia and transfusion in patients with cervix cancer: a review

Cited by 129 publications

References 31 publications

Clinical and Pathological Factors Related to the Prognosis of Chinese Patients with Stage Ⅰb To Ⅱb Cervical Cancer

Clinical and Pathological Factors Related to the Prognosis of Chinese Patients with Stage Ⅰb To Ⅱb Cervical Cancer

Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer

Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer

Contact Info

Product

Resources

About